Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 14, 2005 - Issue 11
Submit an article Journal homepage
166
Views
50
CrossRef citations to date
0
Altmetric
Review

Protease inhibitors as potential disease-modifying therapeutics for Alzheimer’s disease

Dirk Beher Department of Molecular & Cellular Neuroscience, Merck Sharp & Dohme Research Laboratories, The Neuroscience Research Centre, Terlings Park, Harlow, Essex CM20 2QR, UK. [email protected]
&
Samuel L Graham Department of Medicinal Chemistry, Merck Research Laboratories, West Point, PA 19486, USA. [email protected]
Pages 1385-1409 | Published online: 28 Oct 2005

Bibliography

  • HY LX, KELLER DM: Prevalence of AD among whites: a summary by levels of severity. Neurology (2000) 55(2):198–204.
  • GOEDERT M, WISCHIK CM, RA, WALKER JE, A: Cloning and sequencing of the cDNA encoding a core protein of the paired filament of Alzheimer's disease: as the microtubule-associated protein tau. Proc. Natl. Acad. Sci. USA1988) 85(10:4051–4055.
  • GOEDERT M, SISODIA SS, PRICE DL: Neurofibrillary tangles and 13-amyloid deposits in Alzheimer's disease. Curr. Opin. Neurobiol (1991) 1(3):441–447.
  • GLENNER GG, WONG CW: Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular protein. Biochem. Biophys.. Commun. (1984) 120(3):885–890.
  • MASTERS CL, SIMMS G, NA et al.: Amyloid plaque core protein in Alzheimer's disease and Down's syndrome. Proc. Natl. Acad. Sci. USA (1985) 82(12):4245–4249.
  • KANG J, LEMAIRE HG, A et al: The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature (1987) 325(6106):733–736.
  • HAASS C, SCHLOSSMACHER MG, HUNG AY et al.: Amyloid 0-peptide is produced by cultured cells during normal metabolism. Nature (1992) 359(6393)322–325.
  • SPILLANTINI MG, MURRELL JR, GOEDERT M et al: Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc. Nati Acad. Sci. USA (1998) 95(13):7737–7741.
  • HUTTON M, LENDON CL, RIZZU P et al.: Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature (1998) 393(6686):702–705.
  • ODDO S, CACCAMO A, JD et al: Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular AB and synaptic dysfunction. Neuron (2003) 39(3):409–421.
  • ODDO S, BILLINGS L, KESSLAK JP, CRIBBS DH, LAFERLA FM: AB immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron (2004) 43(3):321–332.
  • HARDY JA, HIGGINS GA: Alzheimer's disease: the amyloid cascade hypothesis. Science (1992) 256(5054):184–185.
  • MULLAN M, CRAWFORD F, K et al.: A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of 0-amyloid. Nat. Genet. (1992) 1(5):345–347.
  • GOATE A, CHARTIER-HARLIN MC, MULLAN M et al: Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature (1991) 349(6311):704–706.
  • MURRELL J, FARLOW M, GHETTI B, BENSON MD: A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease. Science (1991) 254(5028)97–99.
  • NARUSE S, IGARASHI S, H etal: Mis-sense mutation Val-Ile in exon 17 of amyloid precursor protein gene in Japanese familial Alzheimer's disease. Lancet (1991) 337(8747):978–979.
  • ROGAEV El, SHERRINGTON R, ROGAEVA EA et al.: Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature (1995) 376(6543):775–778.
  • SHERRINGTON R, ROGAEV El, LIANG Y et al.: Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature (1995) 375(6534):754–760.
  • LEVY-LAHAD E, WASCO W, P et al: Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science (1995) 269(5226):973–977.
  • LEVY-LAHAD E, WIJSMAN EM, NEMENS E et al.: A familial Alzheimer's disease locus on chromosome 1. Science (1995) 269(5226):970–973.
  • HARDY J: Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci. (1997) 20(4):154–159.
  • HARDY J: The Alzheimer family of diseases: many etiologies, one pathogenesis? Proc. Natl. Acad. Sci. USA (1997) 94(6):2095–2097.
  • LAMBERT MP, BARLOW AK, CHROMY BA et al: Diffusible, nonfibrillar ligands derived from A131-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. USA (1998) 95(11):6448–6453.
  • KLEIN WL: AB toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets. Neurochetn. Int. (2002) 41(5):345–352.
  • GONG Y, CHANG L, VIOLA KL et al: Alzheimer's disease-affected brain: presence of oligomeric A 13 ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc. Natl. Acad. Sci. USA (2003) 100(18):10417–10422.
  • TANZI RE, BERTRAM L: Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell (2005) 120(4):545–555.
  • LEISSRING MA, FARRIS W, CHANG AY et al: Enhanced proteolysis of 0-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron (2003) 40(6):1087–1093.
  • IWATA N, TSUBUKI S, TAKAKI Y et al.: Identification of the major A131-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat. Med. (2000) 6(2):143–150.
  • DEMATTOS RB, BALES KR, CUMMINS DJ et al: Peripheral anti-A13 antibody alters CNS and plasma A 13 clearance and decreases brain A 13 burden in a mouse model of Alzheimer's disease.. Natl. Acad. Sci. USA (2001) 98(15)8850–8855.
  • CITRON M, OLTERSDORF T, HAASS C et al: Mutation of the 0-amyloid precursor protein in familial Alzheimer's disease increases 3-protein production. Nature (1992) 360(6405):672–674.
  • NEVE RL, FINCH EA, DAWES LR: Expression of the Alzheimer amyloid precursor gene transcripts in the human brain. Neuron (1988) 1(8):669–677.
  • SPILLANTINI MG, HUNT SP, J, GOEDERT M: Expression and cellular localization of amyloid 3-protein precursor transcripts in normal human brain and in Alzheimer's disease. Brain Res. Mol. Brain Res. (1989) 6(2-3):143–150.
  • HEBERT SS, SERNEELS L, T et al: Coordinated and widespread expression of y-secretase in vivo: evidence for size and molecular heterogeneity. Neurobiol. Dis. (2004) 17(2):260–272.
  • VASSAR R, BENNETT BD,-KHAN S et al: 3-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science (1999) 286(5440):735–741.
  • ••First report describing the discovery ofBACE1.
  • GHISO J, MATSUBARA E, A et al.: The cerebrospinal-fluid soluble form of Alzheimer's amyloid is complexed to SP-40,40apolipoprotein n, an inhibitor of the complement membrane-attack complex.. J. (1993) 293\(Part 1)27–30.
  • DEMATTOS RB, CIRRITO JR, PARSADANIAN M et al.: ApoE and clusterin cooperatively suppress AB levels and deposition. Evidence that ApoE regulates extracellular AB metabolism in vivo. Neuron (2004) 41(2):193–202.
  • BRIGHTMAN MW, REESE TS: Junctions between intimately apposed cell membranes in the vertebrate brain. Cell Biol. (1969) 40(3):648–677.
  • CSERR HF, BUNDGAARD M: Blood-brain interfaces in vertebrates: a comparative approach. Am. Physiol (1984) 246(3 Part 2):R277–R288.
  • ZLOKOVIC BV: Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci. (2005) 28(4):202–208.
  • •Comprehensive review on AB peptide dynamics.
  • DEANE R, WU Z, SAGARE A etal.: LRP/amyloid 0-peptide interaction mediates differential brain efflux of Al3 isoforms. Neuron (2004) 43(3):333–344.
  • DEANE R, DU YS, RK et al.: RAGE mediates amyloid-13 peptide transport across the blood-brain barrier and accumulation in brain. Nat. Med. (2003) 9(7):907–913.
  • ZLOKOVIC BV, MARTEL CL, MATSUBARA E et al.: Glycoprotein 330/ megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer's disease amyloid at the blood-brain and blood-cerebrospinal fluid barriers. Proc. Nati Acad. Sri. USA (1996) 93(9):4229–4234.
  • GAMES D, ADAMS D, R et al.: Alzheimer-type neuropathology in transgenic mice overexpressing V717F 0-amyloid precursor protein. Nature (1995) 373(6514):523–527.
  • HSIAO K, CHAPMAN P, NILSEN S et al: Correlative memory deficits, Al3 elevation, and amyloid plaques in transgenic mice. Science (1996) 274(5284):99–102.
  • KAWARABAYASHI T, YOUNKIN LH, SAIDO TC et al.: Age-dependent changes in brain, CSF, and plasma amyloid (0) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J. Neurosci. (2001) 21(2):372–381.
  • SAVAGE MJ, TRUSKO SP, DS et al.: Turnover of amyloid 0-protein in mouse brain and acute of its level by phorbol ester.. (1998) 18(5):1743–1752.
  • BARTEN DM, GUSS VL, CORSA JA et al.: Dynamics of 0-amyloid reductions in brain, cerebrospinal fluid, and plasma of 0-amyloid precursor protein transgenic mice treated with a y-secretase inhibitor. Phannacol. Exp. Ther. (2005) 312(2):635–643.
  • HOLCOMB L, GORDON MN, McGOWAN E etal.: Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat. Med. (1998) 4(1):97–100.
  • JOHNSON-WOOD K, LEE M, MOTTER R et al.: Amyloid precursor protein processing and A 042 deposition in a transgenic mouse model of Alzheimer's disease. Proc. Nati Acad. Li. USA (1997) 94(4):1550–1555.
  • CIRRITO JR, MAY PC, O'DELL MA et al.: In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-0 metabolism and half-life. J. Neurosci. (2003) 23(26):8844–8853.
  • LAMB BT, SISODIA SS, LAWLER AM et al.: Introduction and expression of the 400 kilobase amyloid precursor protein gene in transgenic mice. Nat. Genet. (1993) 5(1):22–30.
  • ANDERSON JJ, HOLTZ G, BASKIN PP et al: Reductions in 0-amyloid concentrations in vivo by the y-secretase inhibitors BMS-289948 and BMS-299897. Biochem. Phannacol. (2005) 69(4):689–698.
  • BEST JD, JAY MT, OTU F etal.: Quantitative measurement of changes in amyloid-0(40) in the rat brain and cerebrospinal fluid following treatment with the y-secretase inhibitor LY-411575 [1\12-('23)-243, 5-difluoropheny1)-2-hydroxyethanoyll -Ni-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo cll azepin-7-yll-L-alaninamidel. I Phannacol. Exp. Ther. (2005) 313(2):902–908.
  • GRIMWOOD S, HOGG J, JAY MT et al.: Determination of guinea-pig cortical y-secretase activity ex vivo following the systemic administration of a y-secretase inhibitor. Neurophannacology (2005) 48(7):1002–1011.
  • LANZ TA, HOSLEY JD, ADAMS WJ, MERCHANT KM: Studies of Al3 pharmacodynamics in the brain, CSF and plasma in young (plaque-free) Tg2576 mice using the y-secretase inhibitor, LY-411575. Phannacol. Exp. Ther. (2004) 309(1):49–55.
  • ANDREASEN N, MINTHON L, VANMECHELEN E etal.: Cerebrospinal fluid tau and A1342 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment. Neurosci. Lett. (1999) 273(1):5–8.
  • ANDREASEN N, HESSE C, P etal.: Cerebrospinal fluid 0-amyloid(1–42) in Alzheimer's disease: differences between early- and late-onset Alzheimer's disease and stability during the course of disease. Arch. Neurol. (1999) 56(6):673–680.
  • ANDREASEN N, BLENNOW K: CSF biomarkers for mild cognitive impairment and early Alzheimer's disease.. Neurosurg. (2005) 107(3):165–173.
  • WOLFE MS, XIA W, OSTASZEWSKI BL et al.: Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and y-secretase activity. Nature (1999) 398(6727):513–517.
  • ••Postulates that PSN form the catalyticcenter of an aspartyl-type protease thus constitute the long-sought y-secretase enzyme.
  • WEIHOFEN A, BINNS K, MK, ASHMAN K, MARTOGLIO B: Identification of signal peptide peptidase, a presenilin-type aspartic protease. Science (2002) 296(5576):2215–2218.
  • RAWSON RB, ZELENSKI NG, NIJHAWAN D et al.: Complementation cloning of 52P, a gene encoding a putative metalloprotease required for intramembrane cleavage of SREBPs. Mol. Cell (1997) 1(1):47–57.
  • URBAN S, LEE JR, FREEMAN M: Drosophila rhomboid-1 defines a family of putative intramembrane serine proteases. Cell (2001) 107(2):173–182.
  • •This paper and references [60] and [61] describe the identification of different members of the family of intramembrane-type cleaving proteases.
  • OKOCHI M, STEINER H, A et al.: Presenilins mediate a dual intramembranous y-secretase cleavage of Notch-1. EMBO J. (2002) 21(205408–5416.
  • SASTRE M, STEINER H, FUCHS K et al.: Presenilin-dependent y-secretase processing of 0-amyloid precursor protein at a site corresponding to the S3 cleavage of Notch. EMBO Rep. (2001) 2:835–841.
  • WEIDEMANN A, EGGERT S, REINHARD FB et al.: A novel epsilon-cleavage within the transmembrane domain of the Alzheimer amyloid precursor protein demonstrates homology with Notch processing. Biochemistry (2002) 41(02825–2835.
  • FUNAMOTO S, MORISHIMA-KAWASHIMA M, TANIMURA Y et al.: Truncated carboxyl-terminal fragments of 0-amyloid precursor protein are processed to amyloid 0-proteins 40 and 42. Biochemistry (2004) 43(42):13532–13540.
  • QI-TAKAHARA Y,-KAWASHIMA M, TANIMURA Y et al.: Longer forms of amyloid 13 protein: implications for the mechanism of intramembrane cleavage byã-secretase. J. Neurosci. (2005) 25(2):436–445..
  • WANG R, MESCHIA JF, COTTER RJ, SS: Secretion of the â/A4 precursor protein. Identification of cleavage site in cultured mammalian cells.. Biol. Chem. (1991) 266(25):16960–16964.
  • BEHER D, WRIGLEY JD, OWENS AP, MS: Generation of-terminally truncated amyloid-â peptides dependent on ã-secretase activity.. Neurochem. (2002) 82(3):563–575.
  • GU Y, MISONOU H, SATO T et al.: intramembrane cleavage of the â-amyloid precursor protein family ã-secretase-like cleavage of. J. Biol. Chem. (2001) 276(38):35235–35238.
  • WOLFE MS, XIA W, MOORE CL et al.: probes and molecular suggest that Alzheimer’s ã-secretase is an intramembrane-cleaving protease. Biochemistry (1999) 38(15):4720–4727.
  • SHEARMAN MS, BEHER D, EE et al.: L-685,458, an aspartyl transition state mimic, is a potent of amyloid â-protein precursor ã-secretase activity. Biochemistry (2000) 39(30):8698–8704.
  • DE STROOPER B, SAFTIG P, K et al.: Deficiency of-1 inhibits the normal cleavage of precursor protein. Nature (1998) 391(6665):387–390. •• Demonstrates that PSNs are critically for ã-secretase activity.
  • LI YM, XU M, LAI MT et al.: ã-secretatase inhibitors to the active site covalently label 1. Nature (2000) 405:689–694.
  • ESLER WP, KIMBERLY WT, BL et al.: Transition-state inhibitors of ã-secretase bind to presenilin-1. Nat. Cell Biol. (2000) 2:428–434.
  • SEIFFERT D, BRADLEY JD, CM et al.: Presenilin-1 and 2 molecular targets for ã secretase. J. Biol. Chem. (2000) 275:34086–34091.
  • •• Together with references [74] and [75] this demonstrates that PSNs are the for ã-secretase inhibitors and thus the catalytic site of this enzyme.
  • WRIGLEY JD, NUNN EJ, NYABI O al.: Conserved residues within the active site of ã-secretase influence enzyme activity and binding. J. Neurochem. (2004) 90(6):1312–1320.
  • RICHTER C, TANAKA T, YADA RY: of activation of the gastric proteinases: pepsinogen, and prochymosin. Biochem. J. (1998) 335\(Part 3):481–490.
  • KNAPPENBERGER KS, TIAN G, YE X al.: Mechanism of ã-secretase cleavage: is ã-secretase regulated through involving the presenilin-1 9 loop? Biochemistry (2004) 43(20):6208–6218.
  • BEHER D, WRIGLEY JD, NADIN A al.: Pharmacological knock-down of the 1 heterodimer by a novel ã-secretase inhibitor: implications for biology. J. Biol. Chem. (2001) 276(48):45394–45402.
  • ANNAERT WG, ESSELENS C, BAERT V al.: Interaction with telencephalin and the precursor protein predicts a ring for presenilins. Neuron (2001) 32(4):579–589.
  • ESLER WP, KIMBERLY WT, BL et al.: Activitydependent of the presenilin– ã-secretase complex reveals nicastrin and a ã substrate. Proc. Natl. Acad. Sci. USA (2002) 99(5):2720–2725.
  • TIAN G, SOBOTKA-BRINER CD, J et al.: Linear non-competitive of solubilized human ã-secretase pepstatin A methylester, L-685458, and benzodiazepines.. Biol. Chem. (2002) 277:31499–31505.
  • BEHER D, FRICKER M, NADIN A et al.: vitro characterization of the presenilindependent ã-secretase complex using a novel ligand. Biochemistry (2003) 42(27):8133–8142.
  • SHAH S, LEE SF, TABUCHI K et al.: functions as a ã-secretase-substrate. Cell (2005) 122(3):435–447.
  • • Compelling biochemical study that nicastrin is an initial receptor site of ã-secretase.
  • YU G, NISHIMURA M, ARAWAKA S al.: Nicastrin modulates presenilinmediated/glp-1 signal transduction âAPP processing. Nature (2000) 407(6800):48–54.
  • GOUTTE C, TSUNOZAKI M, VA, PRIESS JR: APH-1 is a membrane protein essential for Notch signaling pathway in elegans embryos. Proc. Natl.. Sci. USA (2002) 99(2):775–779.
  • FRANCIS R, McGRATH G, ZHANG J al.: Aph-1 and pen-2 are required for pathway signaling, ã-secretase of âAPP, and presenilin protein. Dev. Cell (2002) 3(1):85–97.
  • • This paper together reference [86] and [87] the identification of novel of the ã-secretase complex.
  • EDBAUER D, WINKLER E, REGULA JT al.: Reconstitution of ã-secretase activity.. Cell Biol. (2003) 5(5):486–488.
  • •• First report on the reconstitution of ã-secretase activity in a cellular system (yeast), which lacks this enzyme; together reference [90] and [91] this implies the enzyme consists of the integral proteins PSN, NCT, Pen-2 and–1.
  • TAKASUGI N, TOMITA T, HAYASHI I al.: The role of presenilin cofactors in the ã-secretase complex. Nature (2003) 422(6930):438–441.
  • KIMBERLY WT, LAVOIE MJ, BL et al.: ã-Secretase is a protein complex comprised of, nicastrin, aph-1, and pen-2.. Natl. Acad. Sci. USA (2003) 42(22):6664–6673
  • WRIGLEY JD, SCHUROV I, NUNN EJ al.: Functional overexpression of ã-secretase reveals protease-independent functions and a critical role of for protease activity. J. Biol. Chem. (2005) 280(13):12523–12535.
  • HAASS C: Take five-BACE and the ã-secretase quartet conduct Alzheimer’s â-peptide generation. EMBO J. (2004) 23(3):483–488.
  • HU Y, FORTINI ME: Different cofactor in ã-secretase assembly: evidence a nicastrin–Aph-1 subcomplex.. Cell Biol. (2003) 161(4):685–690.
  • LAVOIE MJ, FRAERING PC, BL et al.: Assembly of the ã-secretase complex involves early formation an intermediate subcomplex of Aph-1 nicastrin. J. Biol. Chem. (2003) 278(39):37213–37222.
  • KAETHER C, CAPELL A, EDBAUER D al.: The presenilin C-terminus is required ER-retention, nicastrin-binding and C, CAPELL A, EDBAUER D et al: The presenilin C-terminus is required for ER-retention, nicastrin-binding and 1403 Op/n. lnvestig. Drugs (2005) 14(11)-secretase activity. EMBO J. (2004) 23(24):4738–4748.
  • DE STROOPER B: Aph-1, Pen-2, and nicastrin with presenilin generate an active y-secretase complex. Neuron (2003) 38(1):9–12.
  • SHIROTANI K, EDBAUER D, PROKOP S, HAASS C, STEINER H: of distinct y-secretase complexes with different APH-1 variants. J. Biol. Chem. (2004) 279(40):41340–41345.
  • LAI MT, CHEN E, CROUTHAMEL MC eta].: Presenilin-1 and presenilin-2 exhibit distinct yet overlapping y-secretase activities../. Biol. Chem. (2003) 278(25):22475–22481
  • MA G, LIT, PRICE DL, WONG PC: APH-la is the principal mammalian APH-1 isoform present in y-secretase complexes during embryonic development. J. Neurosci. (2005) 25(1):192–198.
  • SERNEELS L, DEJAEGERE T, CRAESSAERTS K et al: Differential contribution of the three Aphl genes to y-secretase activity in vivo. Proc. Natl. Acad. Sci. USA (2005) 102(5):1719–1724.
  • MASTRANGELO P, MATHEWS PM, CHISHTI MA et al.: Dissociated phenotypes in presenilin transgenic mice define functionally distinct y-secretases.. Nati Acad. Sci. USA (2005) 102(25):8972–8977.
  • •Implies together with [101] that different y-secretase enzyme complexes exert different functions in vivo.
  • LICHTENTHALER SF, WANG R, GRIMM H et al.: Mechanism of the cleavage specificity of Alzheimer's disease y-secretase identified by phenylalanine-scanning mutagenesis of the transmembrane domain of the amyloid precursor protein.. Nati Acad. Sci. USA (1999) n96(6):3053–3058.
  • BUXBAUM JD, LIU KN, LUO Y et al: Evidence that tumor necrosis factor a converting enzyme is involved in regulated a-secretase cleavage of the Alzheimer amyloid protein precursor. J. Biol. Chem. (1998) 273(43):27765–27767.
  • POLLACK SJ, LEWIS H: Secretase inhibitors for Alzheimer's disease: challenges of a promiscuous protease. Curr. Opin. Investig. Drugs (2005) 6(1):35–47.
  • SCHEINFELD MH, GHERSI E, K, FOWLKES BJ, D'ADAMIO L: of 13-amyloid precursor-like -1 and -2 by y-secretase regulates transcription../. Biol. Chem. (2002) 277(46):44195–44201.
  • EGGERT S, PALIGA K, SOBA P etal: The proteolytic processing of the amyloid precursor protein gene family members-1 and APLP-2 involves a-,y-,and c-like cleavages. Modulation of APLP-1 processing by Nglycosylation.. Biol. Chem. (2004) 279(18):18146–18156.
  • NI CY, MURPHY MP, GOLDE TE, CARPENTER G: y-Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science (2001) 294(5549):2179–2181.
  • LEE HJ, JUNG KM, HUANG YZ et al: Presenilin-dependent y-secretase-like intramembrane cleavage of ErbB4. J. Biol. Chem. (2002) 277(8):6318–6323.
  • ANDERSSON CX,-RODRIGUEZ J, LAOS S et al: Shedding and y-secretase-mediated intramembrane proteolysis of the mucin-type molecule CD43. Biochem. J. (2005) 387\(Part 2):377–384.
  • LAMMICH S, OKOCHI M, TAKEDA M et al.: Presenilin-dependent intramembrane proteolysis of CD44 leads to the liberation of its intracellular domain and the secretion of an Af3-like peptide../. Biol. Chem. (2002) 277(47)44754–44759.
  • SCHULZ JG, ANNAERT W, J et al: Syndecan 3 intramembrane proteolysis is presenilin/y-secretase-dependent and modulates cytosolic signaling. J. Biol. Chem. (2003) 278(49):48651–48657.
  • KIM DY, INGANO LA, KOVACS DM: Nectin- la, an immunoglobulin-like receptor involved in the formation of synapses, is a substrate for presenilin/y-secretase-like cleavage. J. Biol. Chem. (2002) 277(50:49976–49981.
  • MARAMBAUD P, WEN PH, DUTT A et al: A CBP binding transcriptional repressor produced by the PS1/c-cleavage of N-cadherin is inhibited by PS1 FAD mutations. Cell (2003) 114(5):635–645.
  • MARAMBAUD P, SHIOI J, SERBAN G et al: A presenilin-l/y-secretase cleavage releases the E-cadherin intracellular domain and regulates disassembly of adherens junctions. EMBO J. (2002) 21(8):1948–1956.
  • TANIGUCHI Y, KIM SH, SISODIA SS: Presenilin-dependent `y-secretase' of deleted in colorectal cancer (DCC). J. Biol. Chem. (2003) 278(33):30425–30428.
  • JUNG KM, TANS, LANDMAN N eta].: Regulated intramembrane proteolysis of the p75 neurotrophin receptor modulates its association with the TrItA receptor. J. Biol. Chem. (2003) 278(43):42161–42169.
  • GOWRISHANKAR K, ZEIDLER MG, VINCENZ C: Release of a membrane-bound death domain by y-secretase processing of the p75NTR homolog NRADD. J. Cell Sci. (2004) 117\(Part 18):4099–4111.
  • HAMBSCH B, GRINEVICH V, SEEBURG PH, SCHWARZ MK:-Protocadherins, presenilin-mediated release of C-terminal fragment promotes locus expression. J. Biol. Chem. (2005) 280(16):15888–15897.
  • HAAS IG, FRANK M, VERON N, KEMLER R: Presenilin-dependent processing and nuclear function of y-protocadherins. J. Biol. Chem. (2005) 280(10):9313–9319.
  • KIM DY, INGANO LA, CAREY BW, PETTINGELL WH, KOVACS DM:/y-secretase-mediated cleavage of the voltage-gated sodium channel 02-subunit regulates cell adhesion and migration. J. Biol. Chem. (2005) 280(24):23251–23261.
  • WONG HK, SAKURAI T, OYAMA F et al.: 13 Subunits of voltage-gated sodium channels are novel substrates of 13-site amyloid precursor protein-cleaving enzyme (BACE1) and y-secretase. J. Biol. Chem. (2005) 280(24):23009–23017.
  • COWAN JW, WANG X, GUAN R et al: Growth hormone receptor is a target for presenilin-dependent y-secretase cleavage. J. Biol. Chem. (2005) 280(19):19331–19342.
  • MAY P, REDDY YK, HERZ J: Proteolytic processing of low density lipoprotein receptor-related protein mediates regulated release of its intracellular domain.. Biol. Chem. (2002) 277(20:18736–18743.
  • DE STROOPER B, ANNAERT W, CUPERS P et al: A presenilin-l-dependent y-secretase-like protease mediates release of Notch intracellular domain. Nature (1999) 398(6727):518–522.
  • •First report demonstrating that intramembrane cleavage of the Notch, which is critical for its signalling function, depends on PSN/y-secretase.
  • SIX E, NDIAYE D, LAABI Y et al: The Notch ligand El is sequentially cleaved by an ADAM protease and y-secretase. Proc. Natl. Acad. Sri. USA (2003) 100(13):7638–7643.
  • LAVOIE MJ, SELKOE DJ: The Notch ligands, Jagged and E, are sequentially processed by a-secretase and presenilirdy-secretase and release signaling fragments. J. Biol. Chem. (2003) 278(36):34427–34437.
  • KOPAN R, SCHROETER EH, WEINTRAUB H, NYE JS: Signal transduction by activated mNotch: importance of proteolytic processing and its regulation by the extracellular domain. Proc. Nati Acad. Sri. USA (1996) 93(4):1683–1688.
  • SCHROETER EH, KISSLINGER JA, KOPAN R: Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain. Nature (1998) 393(6683):382–386.
  • •Both this reference and [128] describe the discovery of ligand-induced proteolytic processing of the Notch receptor as a novel paradigm for signal transduction.
  • MUMM JS, SCHROETER EH, SAXENA MT et al.: A ligand-induced extracellular cleavage regulates y-secretase-like proteolytic activation of Notchl. Mol. Cell (2000) 5(2):197–206.
  • BROU C, LOGEAT F, GUPTA N et al: A novel proteolytic cleavage involved in Notch signaling: the role of the disintegrin-metalloprotease TACE. Mol. Cell (2000) 5(2):207–216.
  • ARTAVANIS-TSAKONAS S, K, FORTINI ME: Notch signaling. Science (1995) 268(5208):225–232.
  • WASHBURN T, SCHWEIGHOFFER E, GRID LEY T et al.: Notch activity influences the al3 versus y8 T cell lineage decision. Cell (1997) 88(6):833–843.
  • FRE S, HUYGHE M, MOURIKIS P et al.: Notch signals control the fate of immature progenitor cells in the intestine. Nature (2005) 435(7044):964–968.
  • HARRISON T, BEHER D: y-Secretase inhibitors-from molecular probes to new therapeutics? Prog. Med. Chem. (2003) 41:99–127.
  • HARRISON T, CHURCHER I, BEHER D: y-Secretase as a target for drug in Alzheimer's disease. Curl: Opin. Drug Discov. Bevel. (2004) 7(5):709–719.
  • HIGAKI J, QUON D, ZHONG Z, CORDELL B: Inhibition of 13-amyloid formation identifies proteolytic precursors and subcellular site of catabolism. Neuron (1995) 14(3):651–659.
  • WOLFE MS, CITRON M, DIEHL TS et al.: A substrate-based difluoro ketone selectively inhibits Alzheimer's y-secretase activity.J Med. Chem. (1998) 41(1):6–9.
  • TEALL M, OAKLEY P, HARRISON T et al.: Aryl sulfones: a new class of y-secretase inhibitors. Bioorg. Med. Chem. Lett. (2005) 15(10):2685–2688.
  • CHURCHER I, WILLIAMS S, S et al: Design and synthesis of highly potent benzodiazepine y-secretase inhibitors: preparation of (25,3A)-3-(3,4-difluoropheny0 2 (4 fluorophenyfl-4-hydroxy-N- (0.9-1-methy1-2-oxo-5-phenyl-2,3-dihydro-1H-benzo [e] [1, 4] - diazepin-3-yObutyramide by use of an asymmetric Ireland-Claisen rearrangement.. Chem. (2003) 46(12):2275–2278.
  • NESS D, BOGGS LN, HEPBURN D et al.: Reduced 13-amyloid burden, increased C-99 concentrations and evaluation of neuropathology in the brains of PDAPP mice given LY450139 dihydrate daily by gavage for 5 months. Neurobiol. Aging (2004) 25\(Suppl. 2):5238.
  • DOVEY HF, JOHN V, ANDERSON JP et al.: Functional y-secretase inhibitors reduce 13-amyloid peptide levels in brain. J. Neurochem. (2001) 76(1):173–181.
  • •First demonstration of in vivo efficacy of a y-secretase inhibitor with respect to reduction of AB production after oral dosing.
  • LANZ TA, HIMES CS, PALLANTE G et al.: The y-secretase inhibitor /V [N-(3,5-difluorophenacetyfl-L-alanyfl-..0 phenylglycine t-butyl ester reduces AB levels in vivo in plasma and cerebrospinal fluid in young (plaque-free) and aged (plaque-bearing) Tg2576 mice.. Exp. Ther. (2003) 305(3):864–871.
  • LEWIS HD, PEREZ REVUELTA BI, NADIN A et al: Catalytic site-directed y-secretase complex inhibitors do not discriminate pharmacologically between Notch S3 and 3-APP cleavages. Biochemistry (2003) 42(24):7580–7586.
  • WONG GT, MANFRA D, POULET FM et al.: Chronic treatment with the y- inhibitor LY-411,575 inhibits AB production and alters lymphopoiesis and intestinal cell differentiation. j Biol. Chem. (2004) 279(13):12876–12882.
  • SEARFOSS GH, JORDAN WH, CALLIGARO DO et al.: Adipsin, a biomarker of gastrointestinal toxicity mediated by a functional y-secretase inhibitor. J. Biol. Chem. (2003) 278(46):46107–46116.
  • SIEMERS E, SKINNER M, DEAN RA et al: Safety, Tolerability, and Changes in Amyloid 13 Concentrations After Administration of a y-Secretase Inhibitor in Volunteers. Clin. Neuropharmacol. (2005) 28(3):126–132.
  • WONG PC, ZHENG H, CHEN H et al: Presenilin 1 is required for Notchl and DII1 expression in the paraxial mesoderm. Nature (1997) 387(6630):288–292.
  • SHEN J, BRONSON RT, CHEN DF et al: Skeletal and CNS defects in presenilin-l-deficient mice. Cell (1997) 89(4):629–639.
  • GELING A, STEINER H, WILLEM M, BALLY-CUIF L, HAASS C: A y-secretase inhibitor blocks Notch signaling in vivo and causes a severe neurogenic phenotype in zebrafish. EMBO Rep. (2002) 3(7):688–694.
  • MICCHELLI CA, ESLER WP, KIMBERLY WT et al.: y-Secretase/ presenilin inhibitors for Alzheimer's disease phenocopy Notch mutations in Drosophila. FASEB J. (2003) 17(1):79–81.
  • RADTKE F, WILSON A, HR: Notch signaling in- and B-cell development. Curr. Opin. Immunol. (2004) 16(2):174–179.
  • RADTKE F, WILSON A, MANCINI SJ, MacDONALD HR: Notch regulation of lymphocyte development and function. Nat. Immunol. (2004) 5(3):247–253.
  • DOERFLER P, SHEARMAN MS, PERLMUTTER RM: Presenilin-dependent y-secretase activity modulates thymocyte development. Proc. Nati Acad. Sci. USA (2001) 98(16):9312–9317.
  • HADLAND BK, MANLEY NR, SU D et al.: y-secretase inhibitors repress thymocyte development. Proc. Nati Acad. Sci. USA (2001) 98(13):7487–7491.
  • MILANO J, McKAY J, DAGENAIS C et al: Modulation of notch processing by y-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage Toxicol. Sci. (2004) 82(1):341–358.
  • •First description of differential Notch-related toxicity associated with different types of y-secretase inhibitors.
  • SAITO T, CHIBA S, ICHIKAWA M et al.: Notch2 is preferentially expressed in mature B cells and indispensable for marginal zone B lineage development. Immunity (2003) 18(5):675–685.
  • KURODA K, HAN H, TANI S et al: Regulation of marginal zone B cell development by MINT, a suppressor of Notch/RBP-J signaling pathway. Immunity (2003) 18(2):301–312.
  • TANIGAKI K, HAN H, YAMAMOTO N et al.: Notch-RBP-J signaling is involved in cell fate determination of marginal zone B cells. Nat. Immunol (2002) 3(5):443–450.
  • JENSEN J, PEDERSEN EE, GALANTE P et al.: Control of endodermal endocrine development by Hes-1. Nat. Genet. (2000) 24(1):36–44.
  • VAN ES JH, VAN GUN ME, RICCIO 0 et al.: Notch/y-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature (2005) 435(7044):959–963.
  • ELLISEN LW, BIRD J, WEST DC et al.: TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell (1991) 66(4):649–661.
  • WENG AP, FERRANDO AA, LEE W et al: Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science (2004) 306(5694):269–271.
  • ••Key publication demonstrating a causativerole for aberrant Notch signalling in T-ALL.
  • UYTTENDAELE H, MARAZZI G, WU G et al: Notch4/int-3, a mammary proto-oncogene, is an endothelial cell-specific mammalian Notch gene. Development (1996) 122(7):2251–2259.
  • DAS I, CRAIG C, FUNAHASHI Y et al: Notch oncoproteins depend on y-secretase/ presenilin activity for processing and function. Biol. Chem. (2004) 279(29):30771–30780.
  • PECE S, SERRESI M, SANTOLINI E et al.: Loss of negative regulation by Numb over Notch is relevant to human breast carcinogenesis. Cell Biol. (2004) 167(2):215–221.
  • GUO M, JAN LY, JAN YN: Control of daughter cell fates during asymmetric division: interaction of Numb and Notch. Neuron (1996) 17(1):27–41.
  • RHYU MS, JAN LY, JAN YN: Asymmetric distribution of numb protein during division of the sensory organ precursor cell confers distinct fates to daughter cells. Cell (1994) 76(3):477–491.
  • PARIS D, QUADROS A, PATEL N et al: Inhibition of angiogenesis and tumor growth by 13 and y-secretase inhibitors. Eur. Pharmacol (2005) 514(1):1–15.
  • CURRY CL, REED LL, GOLDE TE et al: y-Secretase inhibitor blocks Notch activation and induces apoptosis in Kaposi's sarcoma tumor cells. Oncogene (2005) 24(42):6333–6344.
  • WEIJZEN S, RIZZO P, BRAID M et al.: Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Nat. Med. (2002) 8(9):979–986.
  • WEGGEN S, ERIKSEN JL, DAS P et al: A subset of NSAIDs lower amyloidogenic Al342 independently of cyclooxygenase activity. Nature (2001) 414(6860):212–216.
  • ••First demonstration that certain NSAIDscan selectively lower A13(42) production.
  • STEWART WE KAWAS C, M, METTER EJ: Risk of Alzheimer's disease and duration of NSAID. Neurology (1997) 48(3):626–632.
  • ERIKSEN JL, SAGI SA, SMITH TE et al: NSAIDs and enantiomers of flurbiprofen target y-secretase and lower Al3 42 in vivo. Clin. Invest. (2003) 112(3):440–449.
  • MOORE CL, LEATHERWOOD DD, DIEHL TS, SELKOE DJ, WOLFE MS: Difluoro ketone peptidomimetics suggest a large Si pocket for Alzheimer's y-secretase: implications for inhibitor design.. Med. Chem. (2000) 43(18):3434–3442.
  • WEGGEN S, ERIKSEN JL, SAGI SA et al: Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid 13 42 production by direct modulation of y-secretase activity. J. Biol. Chem. (2003) 278(34):31831–31837.
  • SAGI SA, WEGGEN S, ERIKSEN J, GOLDE TE, KOO EH: The non-cyclooxygenase targets of non-steroidal anti-inflammatory drugs, lipoxygenases, peroxisome proliferator-activated receptor, inhibitor of x13 kinase, and NF KB, do not reduce amyloid 13 42 production.. Biol. Chem. (2003) 278(34):31825–31830.
  • ZHOU Y, SU Y, LI B et al: Nonsteroidal anti-inflammatory drugs can lower amyloidogenic Al342 by inhibiting Rho. Science (2003) 302(5648):1215–1217.
  • KUKAR T, MURPHY MP, ERIKSEN JL et al.: Diverse compounds mimic Alzheimer's disease-causing mutations by augmenting Al342 production. Nat. Med. (2005) 11(5):545–550.
  • TAKAHASHI Y, HAYASHI I, Y et al.: Sulindac sulfide is a noncompetitive y-secretase inhibitor that preferentially reduces Al3 42 generation. J. Biol. Chem. (2003) 278(20):18664–18670.
  • BEHER D, CLARKE EE, WRIGLEY JD et al.: Selected non-steroidal anti-inflammatory drugs and their derivatives target y-secretase at a novel site. Evidence for an allosteric mechanism. J. Biol. Chem. (2004) 279(42):43419–43426.
  • FRAERING PC, YEW, STRUB JM et al.: Purification and characterization of the human y-secretase complex. Biochemistry (2004) 43(30):9774–9789.
  • LLE0 A, BEREZOVSKA 0, HERL L et al: Nonsteroidal anti-inflammatory drugs lower Al342 and change presenilin 1 conformation. Nat. Med. (2004) 10(10):1065–1066.
  • •Provides together with [181] direct evidence that certain NSAIDs introduce allosteric changes into PSNsty-secretase.
  • WAGNER SL, KOUNNAS MZ, TYREE CM et al.: Modulators of y-secretase activity that lower Al3-42 levels without affecting Notch proteolytic processing. 7th International Conference AD/PD, Sorrento, Italy (2005):11.
  • SINHA S, ANDERSON JP, BARBOUR R et al.: Purification and cloning of amyloid precursor protein 0-secretase from human brain. Nature (1999) 402(6761):537–540.
  • HUSSAIN I, POWELL D, DR et al.: Identification of a novel aspartic protease (Asp 2) as 13-secretase. Mol. Cell Neurosci. (1999) 14(6):419–427.
  • LIN X, KOELSCH G, WU S et al: Human aspartic protease memapsin 2 cleaves the 0-secretase site of 0-amyloid precursor protein. Proc. Nati Acad. Sci. USA (2000) 97(4):1456–1460.
  • SAUNDERS AJ, KIM T-W, TANZI RE: BACE maps to chromosome 11 and a homolog, BACE2, reside in the obligate Down's syndrome region of chromosome 21. Science (1998) 286:1255a.
  • YAN R, BIENKOWSKI MJ, SHUCK ME et al: Membrane-anchored aspartyl protease with Alzheimer's disease P-secretase activity. Nature (1999) 402(6761):533–537.
  • ••This publication together with [191-194]describes independent efforts that led to the successful cloning of BACE1 and 2 enzymes after this first report by [34].
  • FARZAN M, SCHNITZLER CE, VASILIEVA N, LEUNG D, CHOE H: BACE2, a P-secretase homolog, cleaves at the 13 site and within the amyloid-13 region of the amyloid-13 precursor protein. Proc. Nati Acad. Sci. USA (2000) 97(17):9712–9717.
  • JOHN V, BECK JP, BIENKOWSKI MJ, SINHA S, HEINRIKSON RL: Human 13-secretase (BACE) and BACE inhibitors. J. Med. Chem. (2003) 46(22):4625–4630.
  • CITRON M: b-Secretase inhibition for the treatment of Alzheimer's disease - promise and challenge. Trends Pharmacol2004) 25(2):92–97.
  • HOLSINGER R, McLEAN C, BEYREUTHER K, MASTERS C, G: Increased expression of the amyloid precursor P-secretase in Alzheimer's disease. Ann. Neurol (2002) 51(6):783–786.
  • FUKUMOTO H, ROSENE DL, MOSS MB et al.: b-secretase activity increases with aging in human, monkey, and mouse brain. Anti: Pathol (2004) 164(2):719–725.
  • LI R, LINDHOLM K, YANG L-B et al: Amyloid 13 peptide load is correlated with increased b-secretase activity in sporadic Alzheimer's disease patients. Proc. Nati Acad. Sci. USA (2004) 101(10):3632–3637.
  • TYLER SJ, DAWBARN D, GK, ALLEN SJ: a- and 13-secretase: profound changes in Alzheimer's disease. Biochem. Biophys. Res. Commun. (2002) 299(3):373–376.
  • YANG L, LINDHOLM K, YAN R et al: Elevated P-secretase expression and enzymatic activity detected in sporadic Alzheimer's disease. Nat. Med. (2003) 9(1):3–4.
  • HOLSINGER R, McLEAN C, COLLINS S, MASTERS C, EVIN G: Increased P-Secretase activity in cerebrospinal fluid of Alzheimer's disease subjects. Ann. Neurol (2004) 55(6):898–899.
  • TAMAGNO E, PAROLA M, BARDINI P et al.: 13-Site APP cleaving enzyme up-regulation induced by 4-hydroxynonenal is mediated by stress-activated protein kinases pathways. I Neurochem. (2005) 92(3):628–636.
  • LEUBA G, WERNLI G, VERNEY A et al: Neuronal and nonneuronal quantitative BACE immunocytochemical expression in the entorhinohippocampal and frontal regions in Alzheimer's disease. Dement. Ceriatr. Cogn. Disord. (2005) 19(0171–183.
  • ROSSNER S, LANGE DOHNA C, ZEITSCHEL U, PEREZ POLO JR: Alzheimer's disease P-secretase BACE1 is not a neuron-specific enzyme. J. Neurochem. (2005) 92(2):226–234.
  • CAI H, WANG Y, McCARTHY D et al: BACE1 is the major P-secretase for generation of A6 peptides by neurons. Nat. Neurasci. (2001) 4(3):233–234.
  • LUO Y, BOLON B, KAHN S et al: Mice deficient in BACE1, the Alzheimer's P-secretase, have normal phenotype and abolished 13-amyloid generation.. Neurasci. (2001) 4(3):231–232.
  • •Together with [208] this report unequivocally demonstrates that BACE1 is the key enzyme for A6 generation in the brain.
  • HARRISON SM, HARPER AJ, HAWKINS J et al: BACE1 (13-secretase) transgenic and knockout mice: identification of neurochemical deficits and behavioral changes. Mol. Cell. Neurosci. (2003) 24(3):646–655.. OHNO M, SAMETSKY E, YOUNKIN L eta].: BACE1 Deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease. Neuron (2004) 41(1):27–33.
  • •Highlights the functional benefits associated with BACE1 inactivation in a mouse model for AD.. KAMENETZ F, TOMITA T, HSIEH H eta].: APP processing and synaptic function. Neuron (2003) 37(6):925–937.
  • DOMINGUEZ D, TOURNOY J, HARTMANN D et al: Phenotypical and biochemical analysis of BACE1 and BACE2 deficient mice. J. Biol. Chem. (2005) 280(35):30797–30806.
  • •This paper and [210] indicate the phenotypic changes associated with genetic inactivation of BACE1.. CHIOCCO MJ, KULNANE LS, L et al.: Altered amyloid-13 and deposition in genomic-based P-secretase transgenic mice.. Biol. Chem. (2004) 279(50):52535–52542.
  • MOHAJERI MH, SAINI KD, NITSCH RM: Transgenic BACE expression in mouse neurons accelerates amyloid plaque pathology. I Neural. Trans. (2004) 111(3):413–425.
  • BODENDORF U, DANNER S, FISCHER F et al: Expression of human P-secretase in the mouse brain increases the steady-state level of 13-amyloid.. (2002) 80(5):799–806.
  • HANIU M, DENIS P, YOUNG Y et al: Characterization of Alzheimer's P-secretase protein BACE. A pepsin family member with unusual properties. j. Biol. Chem. (2000) 275(28):21099–21106.
  • BENNETT BD, DENIS P, HANIU M et al: A furin-like convertase mediates propeptide cleavage of BACE, the Alzheimer's 13 -secretase. J. Biol. Chem. (2000) 275(48):37712–37717.
  • SHI XP, CHEN E, YIN KC et al: The pro domain of P-secretase does not confer strict zymogen-like properties but does assist proper folding of the protease domain. J. Biol. Chem. (2001) 276(13):10366–10373.
  • BENJANNET S, ELAGOZ A, WICKHAM L et al: Post-translational processing of 13-secretase (13-amyloid-converting enzyme) and its ectodomain shedding. The pro- and transmembrane/ cytosolic domains affect its cellular activity and amyloid-13 production. I Biol. Chem. (2001) 276(14):10879–10887.
  • HUANG X-P, CHANG W-P, G eta].: Internalization of exogenously added memapsin 2 (13-secretase) ectodomain by cells Is mediated by amyloid precursor protein. J. Biol. Chem. (2004) 279(36):37886–37894.
  • HUSE JT, BYANT D, YANG Y et al: Endoproteolysis of P-secretase (3-site amyloid precursor protein-cleaving enzyme) within its catalytic domain. Biol. Chem. (2003) 278(19):17141–17149.
  • BENJANNET S, CROMLISH J, DIALLO K, CHRETIEN M, SEIDAH N: The metabolism of 13-amyloid converting enzyme and 13-amyloid precursor protein processing. Biochem. Biophys. Res. Commun. (2004) 325(1):235–242.
  • COLCIAGHI F, MARCELLO E, BORRONI B et al: Platelet APP, 10 and BACE alterations in the early stages of Alzheimer's disease. Neurology2004) 62(3):498–501.
  • GRUNINGER-LEITCH F, D, KUNG E, NELBOCK P, DOBELI H: Substrate and inhibitor profile of BACE (13-secretase) and comparison with other mammalian aspartic proteases. J. Biol. Chem. (2002) 277(7):4687–4693.
  • TOMASSELLI AG, QAHWASH I, EMMONS TL et al: Employing a superior BACE1 cleavage sequence to probe cellular APP processing. J. Neurochem. (2003) 84(5):1006–1017.
  • SHI X, TUGUSHEVA K, BRUCE J et al: Novel mutations introduced at the 13-site of amyloid 13 protein precursor enhance the production of amyloid 13 peptide by BACE1 in vitro and in cells. j Alzheimer. Dis. (2005) 7(2):139–48.
  • TOULOKHONOVA L, METZLER WJ, WITMER MR, COPELAND RA, MARCINKEVICIENE J: Kinetic studies on 13-site amyloid precursor protein-cleaving enzyme (BACE). Confirmation of an iso mechanism. J. Biol. Chem. (2003) 278(7):4582–4589.
  • NORTHROP DB: Follow the protons: a low-barrier hydrogen bond unifies the mechanisms of the aspartic proteases. Acc. Chem. Res. (2001) 34(10):790–797.
  • PATEL S, VUILLARD L, CLEASBY A, MURRAY CW, YON J: Apo and Inhibitor Complex Structures of BACE (13-secretase). Mo/. Biol. (2004) 343(2):407–416.
  • HONG L, HEX, HUANG X, W, TANG J: Structural features of human memapsin 2 (13-secretase) and their biological and pathological implications. Acta Biochim. Biophys. Sin. (2004) 36(12):787–792.
  • KOPCHO LM, MA J, MARCINKEVICIENE J et al.: Comparative studies of active site-ligand interactions among various recombinant constructs of human 13-amyloid precursor protein cleaving enzyme.. Biochem. Biophys. (2003) 410(2):307–316.
  • SIDERA C, LIU C, AUSTEN B: Pro-domain removal in ASP-2 and the cleavage of the amyloid precursor are influenced by pH. BMC Biochemistry (2002) 3(1):25.
  • SCHMECHEL A, STRAUSS M, SCHLICKSUPP A et al: Human BACE Forms Dimers and Colocalizes with APP. J. Biol. Chem. (2004) 279(38):39710–39717.
  • WESTMEYER GG, WILLEM M, LICHTENTHALER SF et al: Dimerization of 13-site 13-amyloid precursor protein-cleaving enzyme. J. Biol. Chem. (2004) 279(50:53205–53212.
  • MARLOW L, CAIN M, PAPPOLLA MA, SAMBAMURTI K: P-Secretase processing of the Alzheimer's amyloid protein precursor (APP). Mol Neurosci. (2003) 20(3):233–239.
  • CUMMING JN, ISELOH U, ME: Design and development of BACE-1 inhibitors. Curr. Opin. Drug Discov. Dem.]. (2004) 7(4):536–556.
  • LARNER AJ: Secretases as therapeutic targets in Alzheimer's disease: patents 2000-2004. Expert Opin. Ther. Patents (2004) 14(10):1403–1420.
  • HUSSAIN I: The Potential for BACE1 inhibitors in the treatment of Alzheimer's disease. 'Drugs (2004) 7(7):653–658.
  • CHANG W-P, KOELSCH G, WONG S et al: In vivo inhibition of Ab production by memapsin 2 (b-secretase) inhibitors. Neurochem. (2004) 89(6):1409–1416.
  • •First published proof-of-concept of in vivo inhibition of BACE1 by an BACE1 Inhibitor.
  • GHOSH AK, DEVASAMUDRAM T, HONG L et al.: Structure-based design of cycloamide-urethane-derived novel inhibitors of human brain memapsin 2 (13-secretase). Bioorg. Med. Chem. Lett. (2005) 15(0:3576–3585.
  • TURNER RT, HONG L, KOELSCH G, GHOSH AK, TANG J: Structural locations and functional roles of new subsites S-5, S-6, and S-7 in memapsin 2 (13-secretase). Biochemistry (2005) 44(1):105–112
  • HONG L, TURNER RT, KOELSCH G et al: Crystal structure of memapsin 2 (13-secretase) in complex with an inhibitor 0M00-3. Biochemistry (2002) 41(36):10963–10967.
  • RIZZI L, ROMEO S: Inhibition of BACE-1 by hydroxyethylsulfide, hydroxyethylamine and hydroxyethylurea isosteric replacements. Lett. Drug Design Discov. (2005) 2(2):109–112.
  • HUB, FAN KY, BRIDGES K et al: Synthesis and SAR of bis-statine based as BACE 1 inhibitors. Bioorg. Med.. Lett. (2004) 14(13):3457–3460.
  • KIMURA T, SHUTO D, HAMADA Y et al.: Design and synthesis of highly active Alzheimer's (3)-secretase (BACE1) inhibitors, KMI-420 and KMI-429, with enhanced chemical stability. Bioorg. Med. Chem. Lett. (2005) 15(1):211–215.
  • COBURN CA, STACHEL SJ, LI YM al.: Identification of a small molecule nonpeptide active site (13)-secretase inhibitor that displays a nontraditional binding mode for aspartyl proteases. Med. Chem. (2004) 47(25): 6117–6119.
  • STACHEL SJ, COBURN CA, TG et al.: Structure-based design of potent and selective cell-permeable inhibitors of human (13)-secretase (BACE-1). I Med. Chem. (2004) 47(26):6447–6450
  • SCHOLEFIELD Z, YATES EA, G et al: Heparan sulfate regulates amyloid precursor protein processing by BACE1, the Alzheimer's b-secretase. Cell Biol. (2003) 163(1):97–107.
  • DE MEYER GRY, DE CLEEN DMM, COOPERS et al: Platelet phagocytosis and processing of b-amyloid precursor protein as a mechanism of macrophage activation in atherosclerosis. Circ. Res. (2002) 90(11):1197–1204.
  • VATTEMI G, ENGEL WK, McFERRIN J et al: BACE1 and BACE2 in pathologic and normal human muscle. Exp. Neurol (2003) 179(2):150–158.
  • PASTORINO L, IKIN AF, LAMPRIANOU S et al: BACE (13-secretase) modulates the processing of APLP2 in vivo. Mol Cell. Neurosci. (2004) 25(4):642–649.
  • LI Q, SUEDHOF TC: Cleavage of amyloid-13 precursor protein and amyloid-13 precursor-like protein by BACE 1. Biol. Chem. (2004) 279(11):10542–10550.
  • VON ARNIM CAF, KINOSHITA A, PELTAN ID et al.: The LDL-receptor related protein (LRP) is a novel 13 -secretase (BACE 1) substrate. I Biol. Chem. (2005) 280(18):17777–17785
  • YOON I-S, PIETRZIK CU, KANG DE, KOO EH: Sequences from the LRP cytoplasmic domain enhances amyloid 0-protein production via the 0-secretase pathway without altering APP/LRP nuclear signaling. I Biol. Chem. (2005) 280(20):20140–20147
  • LICHTENTHALER S, D, WESTMEYER G et al.: The cell adhesion protein P-selectin glycoprotein ligand-1 is a substrate for the aspartyl protease BACE1. I Biol. Chem. (2003) 278(49):48713–48719.
  • KITAZUME S, TACHIDA Y, OKA R et al: Alzheimer's 0-secretase, 0-site amyloid precursor protein-cleaving enzyme, is responsible for cleavage secretion of a Golgi-resident sialyltransferase. Proc. Natl. Acad. Sci. USA (2001) 98(24):13554–13559.
  • KITAZUME S, TACHIDA Y, OKA R et al.: Characterization of a2,6sialyltransferase cleavage by Alzheimer's 0-secretase (BACE1). J. Biol. Chem. (2003) 278(17):14865–14871.
  • KITAZUME S, NAKAGAWA K, OKA R et al: hi vivo cleavage of a 2,6-sialyltransferase by Alzheimer 0-secretase. J. Biol. Chem. (2005) 280(9):8589–8595.
  • WEIHOFEN A, LEMBERG MK, FRIEDMANN E et al: Targeting presenilin-type aspartic protease signal peptide peptidase with y-secretase inhibitors. J. Biol. Chem. (2003) 278(19):16528–16533.
  • LAMMICH S, KOJRO E, POSTINA R et al: Constitutive and regulated a-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease. Proc. Nati Acad. Sci. USA (1999) 96(7):3922–3927.
  • GHISO J, SHAYO M, CALERO M et al: Systemic catabolism of Alzheimer's A1340 and A1342. J. Biol. Chem. (2004) 279(44):45897–45908.
  • DOAN A, THINAKARAN G, DR et al: Protein topology of presenilin 1. Neuron (1996) 17(5):1023–1030.
  • FORTNA RR, CRYSTAL AS, VA et al.: Membrane topology and nicastrin-enhanced endoproteolysis of APH-1, a component of the y-secretase complex. ./. Biol. Chem. (2004) 279(5):3685–3693.
  • CRYSTAL AS, MORAIS VA, TC et al.: Membrane topology of y-secretase component PEN-2.. Chem. (2003) 278(22):20117–20123.
  • THINAKARAN G, BORCHELT DR, LEE MK et al.: Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo. Neuron (1996) 17(1):181–190.
  • DUNN BM: Structure and mechanism of the pepsin-like family of aspartic peptidases. Chem. Rev. (2002) 102(12):4431–4458.
  • TYNDALL JD, NALL T, FAIRLIE DP: Proteases universally recognize 13 strands in their active sites. Chem. Rev. (2005) 105(3):973–999.
  • LI M, PHYLIP LH, LEES WE et al: The aspartic proteinase from cerevisiae folds its own into a helix. Nat. Struct. Biol.2000) 7(2):113–117.

Websites

  • http://www.myriad.com/alzheimers/ phase2_ad.php Genetics, Inc. website.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.